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TREATMENT OF IRON DEFICIENCY IN PEDIATRIC PATIENTS WITH 
INFLAMMATORY BOWEL DISEASE  
JONATHAN SPAAN 
ABSTRACT 
 Iron deficiency anemia (IDA) is the most common extraintestinal complication 
encountered in patients with Inflammatory Bowel Disease (IBD), and it is more prevalent 
in pediatric patients compared to adults (Rogler and Vavricka). The inflammation and 
blood loss from the disease impacts both the absorption and storage of iron in the body 
(Rogler and Vavricka). With the intent of establishing a standard of care for IDA 
treatment in patients with IBD, we conducted a prospective study of 104 consecutive 
pediatric patients to assess the safety and efficacy of intravenous (IV) iron therapy 
compared to oral therapy and no treatment, as well as the effects of iron therapy on 
patient quality of life. Efficacy was assessed by comparing the change in hemoglobin 
levels in the interval between admission to outpatient follow-up.  The average time to the 
first ambulatory follow-up was 29.08 days. 69 patients received IV iron therapy, 17 
patients received oral iron supplementation, and 18 patients had no treatment. Treatment 
with IV iron resulted in a statistically significant increase in hemoglobin levels (2.00 g/dL 
± 1.57 g/dL, as mean ± standard deviation) from admission to the first follow-up 
ambulatory appointment (p < .0001). Patients receiving IV iron therapy also experienced 
a significantly greater mean increase in hemoglobin levels than those treated with oral 
iron (p = .0084) or no treatment (p = .0018). Further, patients treated with IV iron 
experienced a significant increase in their quality of life at follow-up compared to 
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admission as measured by the Impact-III questionnaire (p = .0179). Our study illustrates 
the importance of screening pediatric patients with IBD for IDA and suggests that IV iron 
treatment is safe and more effective in raising hematologic and iron measures than orally-
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Inflammatory Bowel Disease (IBD)  
Inflammatory bowel disease (IBD) is a chronic disease in the gastrointestinal (GI) 
tract defined by relapsing courses of inflammation (Van de Vijver et al.) (Figure 1). The 
two most common classifications of IBD are Crohn disease (CD) and ulcerative colitis 
(UC), which are primarily distinguished by the location of the observed inflammation 
(Rosen et al.). In patients with CD, the inflammation may present in any area of the 
gastrointestinal tract extending from the mouth to the anus, with inflammation most 
commonly occurring in the terminal ileum and colon (Rosen et al.) (Figure 2). Further, 
the CD can manifest as an inflammatory, penetrating, or stricturing phenotype (Rosen et 
al.). Alternatively, UC is defined by continuous inflammation of the colon that begins in 
the rectum (Rosen et al.) (Figure 2). The third and least common subcategory of IBD is 
indeterminate colitis (IC). A provisional diagnosis of IC is given to patients whose 
clinical, endoscopic, and histologic findings could be consistent with a diagnosis of either 
CD or UC (Rosen et al.).  
 IBD symptoms include abdominal pain, diarrhea, bloody stools, fatigue, fever, 
and weight loss (Keethy et al.). Additional symptoms observed in patients diagnosed with 
IBD in early childhood or adolescence include delays in linear growth or physical 
development, as well as the impact on social development (Rufo and Bousvaros) (Table 
1). Also, patients with IBD are at risk for nutritional and micronutrient deficiencies, 
including folate, iron, and Vitamin D, as well as a heightened risk for colon cancer (Rufo 
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and Bousvaros). Approximately 20-25% of patients with IBD present before the age of 
20 (Rosen et al.). The incidence of pediatric IBD is roughly 10 per 100,000 children in 
the United States and Canada.  It is continuing to rise, with a prevalence of 100 to 200 per 
100,000 children (Rosen et al.).  
 Abnormal laboratory findings are very common among patients with IBD, 
including anemia, hypoalbuminemia, thrombocytosis, and increased levels of 
inflammatory markers (Rosen et al.). Histologic examination of biopsy specimens 
obtained from patients with IBD generally demonstrates evidence of acute or chronic 
active inflammation, manifest as mucin depletion or crypt loss or branching (Rosen et 
al.). Noncaseating granulomas are observed in approximately sixty percent of patients 
with CD, and their identification can help to differentiate patients with CD from those 
with UC (Rosen et al.).  
 Although the exact pathogenesis of IBD has not been fully elucidated, existing 
data point to a few likely mechanisms.  One hypothesis suggests that the gut microbiota 
plays a significant role in mediating either the initiation or resolution of intestinal 
inflammation when an abnormal immune response is initiated in a genetically susceptible 
host (Matsuoka and Kanai). It is clear that genetics plays a role, as IBD presenting in very 
young children can be the result of mutations in specific genes such as IL-10 (Shouval 
and Rufo). Further, the compelling escalation of IBD incidence has paralleled changes in 
diet and lifestyle habits in developed and developing regions, suggesting that 
environmental factors may also play a role in the pathogenesis of IBD (Shouval and 
Rufo). One of the dietary changes that is thought to play a particularly important role in 
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the rising incidence of IBD is increased exposure to the saturated fatty acids found in red 
meats and other animal-derived by-products (Shouval and Rufo). Environmental factors, 
including smoking, antibiotic use, pollution, and psychosocial stressors, have all been 
implicated in driving (and typically reducing) the diversity of the intestinal microbiome 
to more of an inflammatory phenotype (Shouval and Rufo).  
 The goal of IBD therapy is centered on minimizing symptoms and increasing 
patient quality of life (Rosen et al.). IBD treatment has continued to make strides, 
particularly in the development of medications predicated on novel mechanistic 
approaches. Current treatment options include biologics targeting tumor necrosis factor 
(TNF) and other regulatory pathways, immunomodulators, corticosteroids, nutrition 
therapy, and aminosalicylate therapies (Rosen et al.).  
 
Disease Indices: PCDAI and PUCAI 
 A disease activity score can be calculated in pediatric patients with CD using 
available indices, including the Pediatric Crohn Disease Activity Index (PCDAI) and the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) (Turner et al.). The PCDAI was 
created by a panel of IBD experts and validated at numerous pediatric centers (J. Hyams 
et al.). PCDAI scores were found to be consistent with the physicians’ general assessment 
of the disease, validating PCDAI as an acceptable measure in pediatric patients with CD 
(J. Hyams et al.).  The fundamental difference between the PCDAI and the Crohn 
Disease Activity Index (CDAI) is that the PCDAI encompasses growth parameters and 
laboratory measures while minimizing the weight of subjective parameters (J. Hyams et 
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al.). The PCDAI assesses disease activity along multiple dimensions, including history, 
physical examination, growth parameters, and laboratory tests, each of which contains 
subitems (J. Hyams et al.) (Table 2). Individual components are measured on a three-
point scale (zero, five, or ten), and a total score can range from zero to one hundred, with 
higher scores signifying more active disease (J. Hyams et al.). A score of less than ten 
signifies inactive disease; scores ranging from 11 to 30 equate to mild disease activity, 
and scores above 30 reflect moderate to severe disease extent (J. Hyams et al.). Unlike 
the management of CD, in which the CDAI is the internationally recognized gold-
standard for assessing disease activity, there is no such equivalent for gauging disease 
activity in patients with UC (Turner et al.). The most common UC assessment in adult 
clinical trials is the Mayo score; however, this requires a sigmoidoscopy at each time 
point, which is less favorable in pediatric patients (Turner et al.). This led to the 
development of the PUCAI scoring, which has proven to correlate with the more invasive 
Mayo Score (Turner et al.). The PUCAI rates patients with UC along six dimensions: 
abdominal pain, rectal bleeding, stool consistency, number of stools in the last twenty-
four hours, the presence or absence of nocturnal stools, and the patient’s current activity 
level (Turner et al.) (Table 3). The PUCAI score ranges from 0 to 85.  Patients with 
composite PUCAI scores under ten have inactive disease or are considered to be in 
remission, those with scores from 10-34 have mild disease activity, scores from 35-64  
indicate moderate disease activity, and patients with PUCAI scores from 65 to 85 have 
severe disease (Turner et al.). A clinically meaningful improvement in a patient’s PUCAI 
score is defined as a reduction of 15-20 points (Turner et al.).  
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 Although disease indices are a great tool in disease assessment, there are some 
shortfalls, as no disease activity index firmly characterizes disease state in every clinical 
circumstance, and existing metrics rely on subjective reporting practices that may change 
over time or across pediatric centers (Turner et al.).   
 
Iron  
 Iron plays a significant role in the majority of living organisms and functions in 
numerous metabolic processes, including oxygen and electron transport, as well as 
deoxyribonucleic acid (DNA) synthesis (Abbaspour et al.). In humans, the body needs 
iron for the operation of the oxygen transport proteins hemoglobin and myoglobin, as 
well as the production of mitochondrial enzymes involved in electron transport and 
oxidation-reduction reactions (Abbaspour et al.).  
 The metabolism of iron is a very regulated process that tightly balances iron 
absorption and utilization.  There is no process in place to regulate iron extrusion from 
the body (Colins et al.). Under appropriate circumstances, dietary iron is absorbed into 
the enterocytes lining the duodenum and jejunum (Colins et al.) (Figure 3). The majority 
of dietary non-heme iron (including that found in vegetables, grains, and fruit) exists in 
the Fe3+ state and must first be reduced to Fe2+ before being transported across the brush 
border membrane (Donovan et al.). Divalent metal transporter 1 (DMT1) is the primary 
transporter involved in Fe2+  and is active in low pH environments as its transport is 
proton-dependent (Donovan et al.). After being transported across the membrane, the 
course of the iron is dependent on the current overall physiological environment 
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(Donovan et al.). When the body has a surplus of iron, Fe2+ remains caged in the 
enterocyte, bound to ferritin, and is lost in the stool when the intestinal epithelial cell is 
physiologically sloughed (Donovan et al.). In contrast, in the context of iron deficiency, 
Fe2+ is transported across the basolateral membrane of the enterocyte by ferroportin-1, 
where it is re-oxidized to Fe3+ and transported in the serum bound to transferrin 
(Donovan et al.).  
 This tightly regulated paradigm of iron sequestration and release is conserved 
across numerous cell types, including macrophages, erythrocytes, hepatocytes, and 
epithelial cells.  The central pathway regulating this process is centered on the hepcidin-
ferroportin axis (Cornelissen et al.) (Figure 4). High iron levels in the blood trigger the 
translation and secretion of hepcidin from the liver (Cornelissen et al.). Circulating 
hepcidin binds to and induces the degradation of ferroportin.  This decrease ferroportin 
bioavailability hinders the subsequent transport of Fe2+ across the epithelial (or 
phagocyte) membrane and into the blood, resulting in a decrease in available iron 
(Cornelissen et al.). On the contrary, hepcidin expression is reduced during periods of 
iron deficiency, thereby increasing ferroportin activity and subsequent systemic iron 
absorption (Cornelissen et al.).  
 
Iron Deficiency Anemia in IBD 
 Iron deficiency is the most prevalent cause of iron deficiency anemia (IDA), 
which has increasingly become a global health issue (Cornelissen et al.). The World 
Health Organization (WHO) defines IDA as a decrease in blood hemoglobin 
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concentration below 12 g/dL (Stein and Dignass). IDA is the most common 
extraintestinal manifestation in patients with IBD and is more frequent in pediatric 
patients than adults (Egberg et al.). Iron deficiency is observed in about 60-80% of IBD 
patients, and anemia is present in about one-third of patients with IBD (Stein and 
Dignass). Anemia can hinder linear growth and development, lower the threshold for 
headaches, impair cognition, and result in affected patients feeling fatigued, dizzy, and 
tachycardic (Stein and Dignass).  
 One of the predominant causes of decreased iron bioavailability in patients with 
IBD relates to the direct and indirect effects of the underlying disease (Rogler and 
Vavricka). Active inflammation typically results in excessive iron losses, driven by 
ongoing visual or occult blood losses in the stool (Rogler and Vavricka). An additional 
mechanism of decreased iron bioavailability in patients with IBD is mediated hepcidin. 
Hepcidin is not only regulated by iron stores, but also by ambient levels of pro-
inflammatory cytokines such as interleukin-6.  As such, inflammation-mediated hepcidin 
overexpression decreases the release of iron from enterocytes and phagocytes (Rogler 
and Vavricka).  
 Iron supplementation therapy for the treatment for IDA and can be delivered 
either orally or intravenously (Stein and Dignass). Iron therapy is essential, as studies 
have shown that treating IBD alone does not cause a significant increase in the patient’s 
hemoglobin level (Egberg et al.). Oral supplementation has been the therapy of choice for 
many years. It increases hemoglobin levels in hospitalized patients with IBD during the 
interval between their discharge from the hospital and when next checked at their 
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subsequent outpatient follow-up appointments (Egberg et al.). However, there has been a 
recent shift in the treatment paradigm favoring the use of parenteral (IV) iron therapy due 
to the belief that oral iron is generally not well-tolerated,  poorly absorbed, and displays 
decreased bioavailability in patients with IBD (Egberg et al.). Further, since over 90% of 
ingested iron remains unabsorbed, oral iron therapy has the potential for adverse effects 
in patients with IBD patients, including nausea and diarrhea (Stein and Dignass).  
 There are currently six different formulations of intravenous iron therapy 
approved for use in the treatment of IDA (Stein and Dignass) (Table 4). Iron Sucrose has 
become the standard of care for use in patients with IBD as a result of its favorable safety 
and efficacy profiles (Stein and Dignass). The efficacy of iron sucrose was confirmed in a 
study in which it was administered to seventy pediatric patients with IDA and IBD, 
including 20 patients with UC, and 50 patients with CD (Mamula et al.). No significant 
adverse events were reported following IV iron treatment (Mamula et al.). Iron sucrose’s 
safety was further documented in a study in which thirty-three adult patients were 
administered this agent (Khalil et al.). A down-side of intravenous iron therapy is that it 
is time-consuming and can take hours to complete an infusion, depending upon the IV 
iron preparation that is chosen and the dosage being administered. This logistic 
inconvenience is offset by the increased bioavailability of parenteral iron administration 






Quality of Life Measures  
 Health-Related quality of life (HRQOL) measures are meaningful in a clinical 
study as the information that they gather will gauge the efficacy of any treatment from 
the patient’s perspective (Griffiths et al.). This is paramount in patients with chronic 
diseases, such as IBD, which may affect the patient in ways that extend beyond their 
physical health (Abdovic et al.). Not only do pediatric patients with IBD suffer from 
physical symptoms, including abdominal pain and diarrhea, but they also report higher 
rates of depression when compared to control populations (Keethy et al.).  
 The Impact-III and Pediatric Quality of Life Inventory (PedsQL) metrics are 
presently the two most prominent questionnaires in use for the measurement of HRQOL 
in pediatric patients (Habibi et al.). The Impact-III is comprised of 35 closed questions 
that measure HRQOL along six dimensions, including bowel symptoms, systemic 
symptoms, social functioning, body image treatment and intervention, and emotional 
functioning. Each item is tallied on a one to five scale, and aggregate IMPACT-III scores 
range from 37 to 175, with higher scores indicating a greater quality of life (Abdovic et 
al.). At the conclusion of the questionnaire, there is also an open-ended text box in which 
the patient can choose to include any additional comments they feel are necessary 
(Abdovic et al.).   
 The PedsQL questionnaire is comprised of 23 measurements, and each scored on 
a five-point scale ranging from 0 (Never) to 4 (Almost Always) (Abdovic et al.). The 
ratings are then reverse-scored and transformed into a 0 to 100 scale, with higher scores 
indicating a higher quality of life score (Abdovic et al.). In addition to the total score out 
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of 100, the PedsQL questionnaire also provides two summary scores, including physical 

























	 This study will examine the efficacy of oral and IV iron therapies in patients with 
IBD and IDA, and the data collected will help to advance the development of a 
standardized approach to the management of iron-deficiency in this population.  The 
safety and efficacy of oral and IV iron treatments will be assessed, as well as their impact 
on hematologic and iron parameters. An additional aspect of this research evaluated the 
longitudinal change in individual patient’s QoL measures as indicated by IMPACT-III 
scores. We hypothesize that IV iron supplementation will result in a significant increase 
in the hematologic and iron parameters of patients with IBD and IDA, relative to that 
observed in patients treated with oral iron therapy, as well as to improve the QoL metrics 







Study Design  
	
This prospective cohort study examined consecutive pediatric patients admitted to 
Boston Children’s Hospital’s (BCH) inpatient GI service from 9/05/2017 to 12/4/2019.  
The inclusion criteria for the research consisted of having both an IBD and IDA 
diagnosis. The IBD diagnosis of UC, CD, or IC was either pre-existing or newly 
diagnosed during admission. The presence of IDA was defined as having either low 
hemoglobin (<12 g/dL) or a low reticulocyte hemoglobin levels (<27pg). Patients were 
excluded from the research if they have had prior surgery (including colectomy, small 
bowel restriction, or ileostomy), if the patient presented with an active infection, if they 
did not receive iron therapy, whether due to physician recommendation or their 
individual preference, or lastly if the patient’s laboratory parameters did not fit the 
study’s operational definition of IDA (patient had hemoglobin above 12 g/dL and a 
reticulocyte hemoglobin greater than 27pg).  
 
Patient Selection  
Patient screening for this study was done using Powerchart, the electronic medical 
record system at Boston Children’s Hospital. The GI inpatient list was reviewed daily to 
identify patients with a new or existing IBD diagnosis that had lab values that were 
consistent with IDA and met the inclusion criteria for the study. Hemoglobin and other 
iron studies, including reticulocyte hemoglobin, ferritin, total iron-binding capacity 
(TIBC), and plasma iron, were also abstracted during the initial patient selection process. 
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Once identified, patients admitted to the hospital, along with their parent or legal 
guardian, were approached for consent in the privacy of their room. After being 
consented, enrolled subjects received and completed HRQOL forms. The researcher 
provided further clarity if there was any difficulty understanding or reading the forms. 
These forms were completed at the patient’s first follow-up ambulatory appointment, 
which typically occurred at the main campus at Boston Children’s Hospital or the BCH 
Waltham satellite site. Consent in this study related to the completion of the HRQOL 
forms.  The iron therapy that was being prescribed and administered fell under the scope 
of the standard of care. Once consented, the patient was given a particular study 
identification, void of any personal identifiers such as name or medical record number 
(MRN), for use throughout the study.  
 
Study Data  
Data collected from each patient’s electronic medical record included 
demographic data (date of birth, gender, ethnicity, race), IBD diagnosis, date of 
diagnosis, prior surgeries, anthropomorphic measures, medications both past and present, 
laboratory values, colonoscopy and endoscopy reports, and disease activity scores 
(PUCAI and PCDAI).  Laboratory values abstracted included cell counts, liver panel, 
chemistry panel, inflammatory markers, and iron studies. Iron treatment, whether IV, 
oral, or packed red blood cell (pRBC) therapy, was also recorded. Patients with IDA that 
were discharged without receiving iron therapy (as a result of provider or patient 
preference) were monitored and used as a study control group. The presence or absence 
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of adverse events was noted as well. HRQOL scores were determined using IMPACT-III 
and PedsQL questionnaires, and results were documented. Data points were collected for 
each study subject at multiple time points, including during their inpatient stay, at the 
date of their discharge, and when they were seen for their initial follow-up ambulatory 
appointment.  
 
Data Collection  
Case report forms (CRF) were created using the Research Electronic Data 
Capture (REDCap). REDCap is a secure and HIPPA compliant, web-based, application 
used to build and manage databases to support clinical and research studies. The CRF 
was broken down into eight discrete domains, including general demographic data, 
anthropomorphic measurements, medications, relevant laboratory studies, treatment 
decisions, and colonoscopy reports, as well as the results of PedsQL and IMPACT-III 
questionnaires. This data set will be used to both test hypotheses related to the present 
study, as well as to pose further questions regarding the evaluation and management of 
IDA in pediatric patients with IBD. Appendix 3 displays the REDCap forms used for data 
collection in this study.  
 
Statistical Analysis  
 Data were analyzed using multiple tests for significance. When comparing the 
increase in hemoglobin levels between types of treatment (IV, oral, no treatment) or 
between individual IV treatments (Infed, Injectafer, Venofer, pRBC), a two-tailed t-test 
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was used to test for a difference in mean between samples. When comparing the 
longitudinal measures of change of hemoglobin level within treatments or HRQOL 
scores from baseline to follow-up, a one-tailed Wilcoxon Signed-Rank Test was used to 
test strictly for improvement over time. P-values less than or equal to .05 were considered 








Patient Demographics and Characteristics  
 The initial screening for this study considered 236 consecutive patients admitted 
to the hospital for the management of their IBD. Of this population, 104 patients (44.1%) 
were identified as being iron deficient with a hemoglobin level <12 g/dL and enrolled in 
the study.  131 patients (55.5%) were identified as not iron deficient and excluded from 
the study, and one additional patient was excluded due to their prior surgical history. Of 
the 104 patients enrolled, 52 (50%) presented with CD, 48 (46.2%) with UC, and four 
(3.8%) with IC. In the study’s cohort, 53.8% (56) were male, and 46.2% (48) were 
female (Table 5). Patients enrolled in the study ranged from 3 to 22 years old.  
 Of the 104 patients enrolled in the study, 86 were treated for their iron deficiency, 
six of which were treated with pRBC, 17 with oral iron, and 60 with intravenous iron. Of 
the subset treated with intravenous iron, 22 were treated with Infed (Iron Dextran), 16 
with Injectafer (Ferric Carboxymaltose), and 19 with Venofer (Iron Sucrose) (Figure 5).  
Six patients were treated with a combination of iron therapies and were excluded from 
the analysis to minimize confounding study variables. Further, an additional six patients 
were excluded due to a lack of attendance at scheduled follow-up outpatient 
appointments during the period in which the study was conducted. The 18 patients who 
were identified as iron deficient but were untreated were used as control subjects. The 




Changes in Anemia between Iron Therapies  
 The interval change in hemoglobin (g/dL) levels observed in patients who 
received intravenous, oral, and no iron therapy was calculated from the time of their 
inpatient admission to their first outpatient follow-up appointment. The three intravenous 
iron therapies used were Infed (Iron Dextran), Injectafer (Ferric Carboxymaltose), and 
Venofer (Iron Sucrose).  All patients treated with oral iron received Ferrous Sulfate. The 
mean dose (± SD) of iron therapy was 699.3 mg ± 427.0 mg for intravenous iron and 
1,549.9 mg ± 1713.6 mg for oral iron (Figure 6). The mean change in hemoglobin at 
follow-up compared to baseline for intravenous, oral, and no iron treatment was 2.00 
g/dL ± 1.57 g/dL, 0.77 g/dL ± 1.56 g/dl, and 0.70 (±) 0.53 respectively (Figure 7). Based 
on the Wilcoxon Signed-Rank Test, there was a statistically significant increase in 
hemoglobin levels from admission to follow-up for both treatment groups, intravenous 
iron (p<.0001), and oral iron (p = .0307), as well as the control group (p = .0006). When 
analyzed between treatment groups from baseline to follow-up using a two-sample t-test, 
there was a significantly greater change in hemoglobin levels of patients treated with 
intravenous therapy compared to those who received oral therapy (p = .0084) and the 
control (no treatment) group (p = .0018). There was not a significant difference in 
measured hemoglobin levels from baseline to follow-up between those subjects that were 






Changes in Anemia Between Intravenous Therapies 
 Next, the changes in hemoglobin levels observed in responses to treatment with 
each intravenous formula were analyzed and compared. A hemoglobin level below 12 
g/dL was defined as being iron deficient. A positive change in hemoglobin level suggests 
an increase in patient well being, and an increase in hemoglobin level of greater than 1 
g/dL was considered to be clinically significant. Although a recommendation for iron 
treatment was provided based on the hospital’s iron dosage formula, the decision to use a 
particular iron formulation and dosage was ultimately at the discretion of the attending 
physician. The mean dosage (± SD) of Infed, Injectafer, and Venofer were 1091.2 mg (± 
361.5 mg), 655.3 mg (± 150.8 mg), and 281.3 (± 169.5 mg), respectively (Figure 6). In 
addition, six patients received pRBC for their iron therapy. The mean change in 
hemoglobin level for patients treated with InFed was 2.04 g/dL (± 1.45 g/dL), 2.29 g/dL 
(± 1.63 g/dL) for Injectafer, 1.13 g/dL (± 1.14 g/dL) for Venofer.  The change in 
hemoglobin was 3.68 g/dL (± 1.59) for patients that had received pRBC (Figure 8). All 
four treatment options demonstrated a statistically significant increase in hemoglobin 
change from admission to follow-up based on the Wilcoxon Signed Rank-Test: Infed (p 
<.0001), Injectafer (p = .0005), Venofer (p=.0011), and pRBC (p <.0001). When 
analyzing the mean change in hemoglobin levels between treatment options using a two-
sample t-test, the response to pRBC transfusion was significantly greater than the 
hemoglobin responses to both Infed (p = .0240) and Venofer (p=.0003), but not Injectafer 
(p = .0886). Patients treated with Injectafer experienced a mean change in hemoglobin 
level that was significantly greater than that observed in patients treated with Venofer (p 
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= .0211), but not Infed (p = .6176). Lastly, the mean change as a result of Infed therapy 
was significantly greater than that observed in patients treated with Venofer (p = .0390).  
 
Change in HRQOL Measures as A Result of Iron Therapy 
 Impact-III forms were used to assess the impact of intravenous iron therapy on 
HRQOL measures in pediatric patients with IBD and IDA. Patients who were treated 
with intravenous iron therapy filled out Impact-III questionnaires in the inpatient setting, 
before receiving iron therapy, and again at their first follow-up appointment. The average 
Impact-III score at baseline was 125.31, and the average score at follow-up was 135.54, 
indicating a positive change of 10.23 (Figure 9). This result demonstrates a statistically 
significant difference in Impact-III HRQOL score in response to intravenous iron therapy 





 IDA is the most frequent extraintestinal manifestation encountered in patients 
with IBD, and it is especially prevalent in pediatric patients (Egberg et al.). IDA can be 
the result of numerous mechanisms, one of which is impaired absorption of iron due to 
inflammation in the intestine (Rogler and Vavricka). Another cause is the loss of iron 
stores due to continuous blood loss and gastrointestinal bleeding (Rogler and Vavricka). 
Further, inflammation results in the release of pro-inflammatory cytokines, which 
stimulate the release and circulation of hepcidin, a protein responsible for degrading the 
Ferroportin-1 transporter on the basolateral membrane of intestinal cells, and thereby 
diminishing bioavailable serum iron (Rogler and Vavricka). Potential symptoms caused 
by IDA include fatigue, headache, dizziness, and tachycardia (Stein and Dignass). The 
reduction of these symptoms is among the primary concerns for the treating physician, as 
treating iron deficiency has improved a patient’s quality of life (Rogler and Vavricka). 
The primary objective of this study was to examine the efficacy and safety of parenteral 
and enteral iron treatments in pediatric patients with IBD at Boston Children’s Hospital 
from 09/05/2017 to 12/04/2019.  
 The central outcome measure used in this study was the patient’s hemoglobin 
level. A hemoglobin level below 12 g/dL was defined as likely resulting from iron 
deficiency. Patients who received IV iron therapy during admission saw a mean increase 
of hemoglobin of 2.00 g/dL. This change in hemoglobin level was significantly greater 
than the mean change due to oral iron therapy (mean = .77 g/dL, p = .0084) or the control 
no treatment group (mean = .70 g/dL, p = .0018). This improved outcome may be due to 
	
21 
several factors including pharmacokinetics since IV iron therapy bypasses intestinal iron 
regulation; it has a bioavailability of 100% and is thus more likely to reach the 
bloodstream and be incorporated into hemoglobin.  However, not all patients in the study 
started with the same baseline hemoglobin level, as inpatient hemoglobin level ranges 
from 4.2 g/dL to 11.9 g/dL. 
Further, the dosage of iron therapy both across and within treatment groups 
varied. This is a result of the dosing requisites related to individual IV formulations.  Low 
molecular weight iron (Infed) has broad-range dosing of up to 2,000 mg per infusion. On 
the other hand, Venofer is used for smaller dosages and cannot be provided at any dose 
above .5 mg/kg.  Injectafer is used as a middle ground for dosage sizes in between 
Venofer and Infed. The average dosage for the formulations for Infed, Injectaer, and 
Venofer in this study was 1091.2 g/dL, 655.3 g/dL, and 281.3 g/dL, respectively. Within 
IV iron therapy treatment, pRBC demonstrated the highest efficacy with an average mean 
increase in hemoglobin level of 3.68 g/dL, followed by Injectafer (2.29 g/dL), Infed (2.04 
g/dL), and Venofer (1.13 g/dL). Data from this study indicate that all four of these 
commercially available iron therapies resulted in statistically significant increases in 
hemoglobin levels from admission to follow-up.  
Patients receiving Infed and Venofer experienced a more significant increase in 
mean hemoglobin levels.  However, this change was not statistically significant (p = 
.6176), as it had been when Infed was compared to Venofer (p = .0211). One concern 
widely expressed by physicians regarding IV iron therapy is the risk of adverse events. In 
our study, this was a priority, and we closely monitored for the development of any 
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adverse events that may have been related to parenteral iron therapy. No adverse events 
were reported for patients who were administered Injecter, Venofer, or pRBC. There was 
one patient who received Infed that experienced what appeared to be an anaphylactic 
reaction. This patient was monitored by the inpatient physicians and teams and sent home 
the following day after spending the night in the hospital before being discharged.  
 Ferrous sulfate, the primary oral iron therapy, was the formulation provided to all 
patients who received oral iron in our study. Oral iron is typically used in patients who 
present with mild anemia or in patients whose IBD symptoms are heading towards a 
remission. In our research, fifteen patients received oral iron. These patients saw a 
statistically significant increase in iron level from admission to follow-up (mean = .77 
g/dL, p = .0307).  However, the mean increase was significantly lower than that observed 
in response to IV iron therapy. Further, the increase in hemoglobin level in response to 
oral therapy was not significantly greater than the control, no treatment, group (p = 
.8608). This may be due to a multitude of reasons; one hypothesis is a decrease in 
bioavailability due to the first-pass effect.  
 Patients who were identified as having IDA but were not treated with either IV or 
oral iron therapy served as the control group for this study. Although these patients 
received no iron supplementation, they demonstrated a statistically significant increase in 
hemoglobin levels from admission to follow-up (mean = .70 g/dL, p = .0006). One 
hypothesis for this occurrence is that changes in personal at-home behavior may have 
played a role in this improvement. For example, they may have adjusted their diet to 
include more iron-rich foods to compensate for their iron deficiency. The protocol in 
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future studies may need to control for at-home behavior such as diet to minimize 
confounding variables, as at home behavior may have also been a factor in hemoglobin 
level changes in the patients who received IV and oral therapy as well. Further, future 
studies are necessary to determine if an adjustment of diet alone can result in a clinically 
significant increase in hemoglobin levels.  
 An additional aim of this research was to identify the effects of IV iron therapy on 
HRQOL. IMPACT-III scores range from 37 to 175, with higher scores indicating an 
improved quality of life. The average improvement in Impact-III score from 
admission/baseline to follow-up was 10.23 points, which was a statistically significant 
change (improvement) in the Impact-III HRQOL score as a result of IV iron therapy (p = 
.01786). Some patients who received IV iron did not complete the Impact-III survey 
either at baseline or at follow-up. This was due to numerous reasons, including difficulty 
in approaching the patient before they received iron therapy or enrolled subjects missing 
or re-scheduling their follow-up appointments. Patients who were unable to fill out these 
surveys were still included in the study and were followed through chart review. Future 
studies may include HRQOL measures in the control population to compare the quality 
of life scores across treatment groups.  
 This study presents several limitations. First, patients were monitored both during 
their inpatient stay and at the time of their first follow-up appointment.  However, the 
interval between these two time points was not standardized. The average time between 
discharge was 29.08 days (SD = 22.95 days), but it ranged from as little as 4 days to 135 
days. As a result of this considerable variation, a patient’s hemoglobin measure at follow-
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up may not be the best representation of the efficacy of parenterally administered iron 
therapy. In addition, patients enrolled in the study were tracked through their first follow-
up appointment. Although some patients were re-admitted to the hospital’s inpatient 
setting and were evaluated there, the majority of patients were seen for their first follow-
up appointment in an out-patient setting. The change in setting from inpatient at baseline 
to out-patient at follow-up may have caused confounding when evaluating HRQOL 
scores. The difference in the environment may have impacted the patient’s mood and 
well-being, thus skewing the score of the questionnaires. Lastly, this study’s protocol did 
not control for the confounding effects that patient demographics may have had on the 
results, including race, gender, and age. The majority of the cohort was white (62.5%) 
and male (53.8%). There was a significant age discrepancy ranging from 3 to 22 years 
old. Fluctuations in hemoglobin levels may result from this age variation, as absorption 
and digestive rates may change over time.  Future research protocols evaluating pediatric 
patients with IBD and IDA should incorporate control populations to better assess for 
primary iron intolerance.  
 In conclusion, IDA is a common co-morbidity in pediatric patients with IBD.  If 
unrecognized or untreated, IDA can result in a wide array of symptoms and impact a 
patient’s quality of life. The data from this study indicate that IV iron therapy is better 
able to raise serum hemoglobin levels relative to alterative agents (either oral iron or no 
therapy). Data collected in this study also demonstrate that IV iron treatment can 
significantly improve the quality of life in pediatric patients with IBD and IDA.  We hope 
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to use data collected in this and other studies to help build a consensus as to how we can 
best screen for and treat IDA in children and adolescents with IDA.    
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Figure 1. Comparison of endoscopic images of the GI mucosa in pediatric patients with 





























































































































































































Figure 7. Change in hemoglobin level from admission to follow-up by treatment type. IV 





















































Figure 8. Change in hemoglobin level from admission to follow-up by IV iron therapy. 






































Figure 9. The change in Impact-III score from admission to follow-up in patients treated 








































Table 1. Prevalence of symptoms associated with CD and UC in pediatric patients with 




































Table 4. Available intravenous iron formulations were available for treating IDA in IBD. 
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